Pages that link to "Q79100306"
Jump to navigation
Jump to search
The following pages link to Once-a-day therapy for HIV infection: a controlled, randomized study in antiretroviral-naive HIV-1-infected patients (Q79100306):
Displaying 15 items.
- Is the recommended once-daily dose of lamivudine optimal in West African HIV-infected children? (Q34045390) (← links)
- Pharmacology and immuno-virologic efficacy of once-a-day HAART in African HIV-infected children: ANRS 12103 phase II trial (Q34997616) (← links)
- Didanosine enteric-coated capsule: current role in patients with HIV-1 infection (Q36864616) (← links)
- Poor Efficacy and Tolerability of Stavudine, Didanosine, and Efavirenz-based Regimen in Treatment-Naive Patients in Senegal (Q37379962) (← links)
- Efavirenz: a decade of clinical experience in the treatment of HIV. (Q37383949) (← links)
- Didanosine population pharmacokinetics in West African human immunodeficiency virus-infected children administered once-daily tablets in relation to efficacy after one year of treatment (Q37392730) (← links)
- Is the recommended dose of efavirenz optimal in young West African human immunodeficiency virus-infected children? (Q37392869) (← links)
- Nucleoside reverse transcriptase inhibitors in combination therapy for HIV patients: systematic review and meta-analysis (Q37744727) (← links)
- A Review of Economic Evaluations of Darunavir Boosted by Low-Dose Ritonavir in Treatment-Experienced Persons Living with HIV Infection (Q37823555) (← links)
- Poor efficacy and tolerability of stavudine, didanosine, and efavirenz-based regimen in treatment-naive patients in Senegal (Q42646909) (← links)
- Cost Effectiveness of Darunavir/Ritonavir 600/100mg bid in Treatment-Experienced, Lopinavir-Naive, Protease Inhibitor-Resistant, HIV-Infected Adults in Belgium, Italy, Sweden and the UK (Q42772430) (← links)
- US Cost Effectiveness of Darunavir/Ritonavir 600/100mg bid in Treatment-Experienced, HIV-Infected Adults with Evidence of Protease Inhibitor Resistance Included in the TITAN Trial (Q42772433) (← links)
- Cost Effectiveness of Darunavir/Ritonavir 600/100mg bid in Protease Inhibitor-Experienced, HIV-1-Infected Adults in Belgium, Italy, Sweden and the UK (Q42772436) (← links)
- Cost Effectiveness of Darunavir/Ritonavir in Highly Treatment-Experienced, HIV-1-Infected Adults in the USA (Q42772440) (← links)
- The far-reaching HAND of cART: cART effects on astrocytes (Q90140528) (← links)